PSNL earnings analysis
What we found in PSNL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Personalis delivered strong Q2 top-line growth, with revenue up 30% to $22.357 million, driven by 52% pharma-services growth and a 442% increase in clinical diagnostic revenue after expanded Medicare coverage. However, expenses grew 43% to $55.948 million, producing a $31.683 million net loss, a negative 150.3% operating margin, and six-month operating cash use of $48.248 million. Liquidity of $212.658 million is meaningful, but the pending Tempus acquisition, loss of Natera revenue, customer concentration, and worsening cash burn dominate the risk profile.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue accelerated to $22.4M
- Q2 revenue increased 30% year over year to $22.357 million from $17.203 million, and increased $6.885 million sequentially from implied Q1 revenue of $15.472 million. Growth came from pharma testing services, up 52% to $16.789 million, and clinical diagnostics, up 442% to $2.541 million.
- Medicare coverage supported clinical ramp
- Clinical revenue growth followed additional Medicare coverage decisions for immunotherapy monitoring and neoadjuvant breast-cancer treatment monitoring in May 2026. Clinical diagnostic revenue reached $2.541 million in Q2, compared with approximately $0.469 million a year earlier.
- Gross margin recovered sequentially
- Gross margin improved sequentially to 21.2% in Q2 from 1.8% in Q1, although it remained below the 27.7% reported in Q2 2025. Revenue exceeded cost of revenue by $4.743 million on $22.357 million of sales.
- Liquidity remains substantial
- The company ended June with $212.658 million of cash, cash equivalents and short-term investments, including $94.0 million of cash and $118.7 million of short-term investments. Management states this liquidity is sufficient for at least the next 12 months.
- Pharma mix increased materially
- The business mix shifted toward pharma and Tempus/Merck-related activity: Merck represented 37% of Q2 revenue and related-party revenue was $8.4 million, versus $1.9 million in Q2 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses widened despite revenue growth
- Losses and operating leverage deteriorated year over year: Q2 net loss was $31.683 million versus $20.056 million, operating loss was $33.591 million versus $21.804 million, and operating margin fell to negative 150.3% from negative 126.8%. Diluted EPS loss widened to $0.30 from $0.23.
- Merger terms create deal and value risk
- The pending Tempus transaction introduces execution and consideration risk. If Tempus' 15-day VWAP is at or below $48.42, the exchange ratio is fixed at 0.3356, so stock consideration can be worth less than $16.25 per Personalis share; a qualifying termination could require a $76.8 million fee.
- Customer and related-party concentration
- Revenue concentration remains elevated: Merck, VA MVP and Moderna accounted for 67% of first-half revenue, while Merck alone was 37% of Q2 revenue. Related-party accounts receivable also rose to $7.5 million at June 30 from $2.5 million at year-end.
- Natera revenue loss remains a headwind
- Natera enterprise revenue has disappeared: enterprise sales were $0 in Q2 2026 versus $2.315 million in Q2 2025, following expiration of minimum-volume commitments after Q2 2025. The company states it no longer has a commercial relationship with Natera.
- Operating cash burn accelerated
- Cash burn increased materially, with six-month operating cash outflow of $48.248 million versus $30.896 million a year earlier. Cash, equivalents and short-term investments declined $27.295 million from $239.953 million at December 31, 2025 to $212.658 million.
- Clinical scaling pressures gross margin
- Clinical expansion is currently margin-dilutive: cost of revenue increased 42% to $17.614 million, including a $3.2 million increase in diagnostic test costs, as tests were sold in advance of Medicare reimbursement to gain market share.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.3
- Gross margin
- 21.2%
- Operating margin
- -150.3%
- Segment
- One reportable segment: advanced cancer genomic testing services.
- Segment
- Pharma testing services: $16.789 million, up 52% year over year.
- Segment
- Population sequencing: $3.000 million, down 9% year over year.
- Segment
- Clinical diagnostic: $2.541 million, up 442% year over year.
- Segment
- Enterprise sales: $0, versus $2.315 million a year earlier.
What they said about what is next.
No formal revenue or EPS range was provided while the Tempus merger is pending. Management did quantify planned capital expenditures of $8.0 million to $10.0 million in 2026, rising to $10.0 million to $12.0 million in each of 2027 and 2028, to expand NeXT Personal Dx capacity.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 7, 2026
- Personalis, Inc. reported disappointing Q1 2026 results with revenue of $15.5 million, reflecting a 25% decrease year-over-year, and an EPS loss of $0.29, slightly worse than the previous year’s loss of $0.18. Key…
- 10-K · February 26, 2026
- Personalis positions itself as an advanced genomics provider for precision oncology with a partner-centric commercialization strategy (notably an expanded Tempus collaboration) and a focus on MRD and comprehensive tumor…
- 10-K · February 27, 2025
- Personalis positions itself as a partner-centric precision oncology diagnostics company focused on ultra‑sensitive MRD (NeXT Personal/NeXT Personal Dx) and comprehensive tumor profiling (NeXT Dx / ImmunoID NeXT),…
- 10-Q · November 6, 2024
- Personalis reported Q3 revenue of $25,709,000, up 40.9% versus Q3 2023 revenue of $18,247,000, and delivered a notable gross margin expansion to 34.0% (gross profit $8,745,000). Operating loss improved to $(14,382,000)…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PSNL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever